Side Effects of Aminoglycosides on the Kidney, Ear and Balance in Cystic Fibrosis

Overview

Journal Thorax

Date 2010 Jul 15

PMID 20627927

Citations 51

Authors

Andrew Prayle

Alan Watson

Heather Fortnum

Alan Smyth

Affiliations

Soon will be listed here.

Abstract

Aminoglycoside antibiotics are a central component of the treatment of pulmonary exacerbations of cystic fibrosis (CF) and slow the decline in lung function which ultimately causes the death of most patients. The prognosis of CF has improved, and thus side effects of treatments have become increasingly important. Observational studies suggest that the morbidity from side effects of aminoglycosides is disturbingly common, and that aggressive treatment may lead to more side effects. This review of the current literature on side effects of aminoglycosides considers the pathophysiological mechanisms, epidemiology and risk factors, investigation of side effects and preventative strategies. Treatments which have shown early promise are identified and areas of future research are discussed.

Citing Articles

Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.

Zhao T, Chen N, Zhang M, Lin L, Lin B, Fang Y Front Microbiol. 2025; 16:1532231.

PMID: 40046300 PMC: 11880276. DOI: 10.3389/fmicb.2025.1532231.

Investigating the Potential Hearing Impairment and Ototoxicity in Children up to Six Years With Cystic Fibrosis After Aminoglycoside Exposure (PIANO-CF Extension).

Schneider-Futschik E, Munro C, Quinlan C, Ranganathan S Pediatr Pulmonol. 2025; 60(2):e27505.

PMID: 39935234 PMC: 11814909. DOI: 10.1002/ppul.27505.

Comparing two-sample log-linear exposure estimation with Bayesian model-informed precision dosing of tobramycin in adult patients with cystic fibrosis.

Tong D, Hughes M, Hu J, Pearson J, Kubiak D, Dionne B Antimicrob Agents Chemother. 2025; 69(2):e0104024.

PMID: 39791873 PMC: 11823644. DOI: 10.1128/aac.01040-24.

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.

Sanders M, Hong E, Chung P, Rao A, Beringer P Clin Pharmacokinet. 2024; 63(12):1701-1709.

PMID: 39581957 PMC: 11649715. DOI: 10.1007/s40262-024-01440-w.

Green synthesis and characterization of polyphenol-coated magnesium-substituted manganese ferrite nanoparticles: Antibacterial and antioxidant properties.

Jamal Salih S Heliyon. 2024; 10(10):e31428.

PMID: 38818154 PMC: 11137518. DOI: 10.1016/j.heliyon.2024.e31428.

References

Conrad D, Stenbit A, Zettner E, Wick I, Eckhardt C, Hardiman G . Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet Genomics. 2008; 18(12):1095-102. DOI: 10.1097/FPC.0b013e328312b072. View

Katbamna B, Homnick D, Marks J . Effects of chronic tobramycin treatment on distortion product otoacoustic emissions. Ear Hear. 1999; 20(5):393-402. DOI: 10.1097/00003446-199910000-00002. View

Schentag J, Lasezkay G, Cumbo T, PLAUT M, Jusko W . Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother. 1978; 13(4):649-56. PMC: 352305. DOI: 10.1128/AAC.13.4.649. View

Bitner-Glindzicz M, Pembrey M, Duncan A, Heron J, Ring S, Hall A . Prevalence of mitochondrial 1555A-->G mutation in European children. N Engl J Med. 2009; 360(6):640-2. DOI: 10.1056/NEJMc0806396. View

Mulheran M, Degg C, Burr S, Morgan D, Stableforth D . Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother. 2001; 45(9):2502-9. PMC: 90684. DOI: 10.1128/AAC.45.9.2502-2509.2001. View

Kang H, Kerstan D, Dai L, Ritchie G, Quamme G . Aminoglycosides inhibit hormone-stimulated Mg2+ uptake in mouse distal convoluted tubule cells. Can J Physiol Pharmacol. 2000; 78(8):595-602. View

Zheng Y, Schachern P, Sone M, Papapella M . Aminoglycoside ototoxicity. Otol Neurotol. 2001; 22(2):266-8. DOI: 10.1097/00129492-200103000-00026. View

Green C, DOERSHUK C, Stern R . Symptomatic hypomagnesemia in cystic fibrosis. J Pediatr. 1985; 107(3):425-8. DOI: 10.1016/s0022-3476(85)80526-6. View

Smyth A, Tan K, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D . Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet. 2005; 365(9459):573-8. DOI: 10.1016/S0140-6736(05)17906-9. View

10.

Abramson A, GORVOY J, Stein T . Cystic fibrosis and hearing loss. Arch Otolaryngol. 1979; 105(6):338-42. DOI: 10.1001/archotol.1979.00790180036007. View

11.

Veenstra D, Harris J, Gibson R, Rosenfeld M, Burke W, Watts C . Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med. 2007; 9(10):695-704. DOI: 10.1097/gim.0b013e318156dd07. View

12.

Vandebona H, Mitchell P, Manwaring N, Griffiths K, Gopinath B, Wang J . Prevalence of mitochondrial 1555A-->G mutation in adults of European descent. N Engl J Med. 2009; 360(6):642-4. DOI: 10.1056/NEJMc0806397. View

13.

Davies J, Alton E, Bush A . Cystic fibrosis. BMJ. 2007; 335(7632):1255-9. PMC: 2137053. DOI: 10.1136/bmj.39391.713229.AD. View

14.

Feldman L, Efrati S, Eviatar E, Abramsohn R, Yarovoy I, Gersch E . Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007; 72(3):359-63. DOI: 10.1038/sj.ki.5002295. View

15.

Samaniego-Picota M, WHELTON A . Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: A Case Presentation and Review of the Literature. Am J Ther. 1996; 3(3):248-257. View

16.

Glass S, Plant N, Spencer D . The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis. J Cyst Fibros. 2005; 4(4):221-5. DOI: 10.1016/j.jcf.2005.09.003. View

17.

Etherington C, Bosomworth M, Clifton I, Peckham D, Conway S . Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros. 2006; 6(1):67-73. DOI: 10.1016/j.jcf.2006.05.013. View

18.

De Broe M, Verbist L, Verpooten G . Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991; 27 Suppl C:41-7. DOI: 10.1093/jac/27.suppl_c.41. View

19.

Holben D, Smith A, Wilmott R . Aminoglycosides lower serum magnesium concentrations in patients with cystic fibrosis: a retrospective study. J Am Diet Assoc. 1995; 95(10):1152-4. DOI: 10.1016/S0002-8223(95)00310-X. View

20.

Pedersen S, Jensen T, Osterhammel D, Osterhammel P . Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother. 1987; 31(4):594-9. PMC: 174783. DOI: 10.1128/AAC.31.4.594. View